IL13Rα2 has been explored clinically as both a CAR-T cell based therapy and as a phase III recombinant protein immunoconjugate target trial for adult glioma with promising outcomes [10,11,33,34], supporting further investigation of immunotherapies or immunoconjugate therapies targeting IL13Rα2 in other diseases with appropriate receptor expression patterns. This evidence concerns the gene IL13RA2 and glioma.